分子剂可以抑制二维基酶活性和炎症信号传递
Francesca Chandler1, Poli Adi Narayana Reddy2, Smita Bhutda3
1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK.
Nature structural & molecular biology
|March 18, 2025
概括
研究人员开发了新的BRISC分子剂 (BLUEs),通过稳定自身抑制的二分体,选择性地抑制BRISC复合物. 这种方法提供了针对炎症信号通路和开发I型干扰素介导疾病治疗方法的新策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 不存在激酶 (DUB) 是细胞信号通路的关键调节者.
- BRCC36异酶复合体 (BRISC) 特别针对K63链接的多基因链在I型干扰素受体 (IFNAR1) 上,影响炎症反应.
- BRCC36是一种Zn2+-依赖的JAMM/MPN DUB,由于其复杂的结构和功能,对选择性抑制剂的开发提出了挑战.
研究的目的:
- 发现和描述BRISC复合体的新型抑制剂.
- 阐明这些新型抑制剂的作用机制.
- 评估在I型干扰素信号传递的背景下抑制BRISC的治疗潜力.
主要方法:
- 开发了BRISC分子剂 (BLUEs),可以稳定BRISC复合体.
- 生物化学测试以评估DUB活动和复杂相互作用.
- 基于细胞的测试来测量干扰素刺激的基因表达和IFNAR1无处不在.
- 对抗抑制剂的BRISC突变体的结构导向设计.
主要成果:
- 蓝色被确定为第一类抑制剂,可以稳定16个子单元的人类BRISC二元体,以自身抑制的形式.
- 这种稳定通过阻断活性位点和与氨酸甲基转移酶2的相互作用来选择性地抑制BRISC活性.
- 蓝色治疗减少了干扰素刺激的基因表达,并增加了细胞中的IFNAR1无处不在,这种效应被耐药突变物消除了.
- 这些发现显示出一种独特的抑制机制,该机制针对大型复合体内的蛋白质-蛋白质相互作用.
结论:
- 布里斯克分子粘剂 (蓝色) 是一种用于选择性抑制布里斯克复合物的新策略.
- 蓝色提供一种潜在的治疗途径,通过调节IFNAR1信号来管理I型干扰素介导疾病.
- 这项研究为通过稳定自身抑制状态来设计大型蛋白质复合物的选择性抑制剂提供了一个新的范式.
相关概念视频
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Regulated Protein Degradation
7.1K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.1K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K


